Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 10-Q Report Quarterly Report
  2. 8-K Event Results of operations
  3. 4 Open-market sale President and CEO sold 18,334 shares at an average $24.20 ($443,744)
  4. DEFA14A Proxy Proxy Materials
  5. DEF 14A Proxy Proxy Statement
  6. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $28.05 ($210,396)
  7. 4 Other disposition 10% owner disposed of 158,764 shares (other)
  8. 4 Open-market sale Chief Medical Officer sold 9,588 shares at an average $26.35 ($252,678)
  9. 4 Open-market sale Chief Medical Officer sold 36,805 shares at an average $25.44 ($936,285)
  10. 4 Open-market sale President and CEO sold 18,333 shares at an average $25.03 ($458,800)
  11. CT ORDER Other Confidential Order
  12. 4 Open-market sale Chief Medical Officer sold 1,000 shares at $25.01 ($25,010)
  13. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $22.58 ($169,313)
  14. S-3ASR Offering Registration Statement
  15. S-8 Other Securities Offered to Employees in Benefit Plans
  16. 10-K Report Annual Report
  17. 8-K Event Results of operations
  18. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $22.17 ($388,000)
  19. 4 Open-market sale President and CEO sold 18,333 shares at an average $22.18 ($406,601)
  20. CT ORDER Other Confidential Order

Page 33 of 40 · 789 filings